Cure8 research brief
If you have IBD and take biologic therapy plus other medicines, inflammation and anti-cytokine treatment may change how your other drugs are metabolized. This review discusses ways researchers are trying to predict and assess those interactions.
Clinicians prescribing biologics for IBD; clinical pharmacologists and researchers; patients on biologics concerned about interactions.
This paper is a literature-based mini-review examining drug–drug interaction (DDI) risk for biologic therapies in inflammatory diseases, with a focus on IBD. The authors summarize evidence that biologics can indirectly affect drug-metabolizing enzymes (especially CYP3A4) through changes in pro-inflammatory cytokines such as IL-6.
They discuss regulatory frameworks (e.g., FDA) and emerging alternative approaches — including endogenous biomarkers like 4β-hydroxycholesterol and pharmacokinetic modeling — to assess DDI risk without dedicated clinical DDI trials in patients.
The review highlights the concept of drug–disease interactions: active inflammation in IBD may suppress CYP activity and alter the clearance of co-prescribed medications, and successful anti-cytokine biologic therapy could reverse those effects and change drug levels.
The authors call for more structured, mechanistic DDI evaluation that integrates cytokine profiling and biomarker-based methods to better predict clinical significance. The article is written for a scientific/clinical audience and summarizes published studies and regulatory discussion rather than reporting new trial data.
The article is a literature-based review (abstract-level summary). Proposed biomarker and modeling strategies are exploratory and not yet routine clinical practice.
Review the original publication for the complete reporting, methods, and context.
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
People with IBD and their clinicians want ways to predict which advanced therapy will work best. This review summarizes current evidence and shows that, despite many studies, no biomarker is reliably ready for routine...
This matters because identifying microbiome patterns linked to infliximab response could help predict which children with IBD are more likely to benefit from the drug and guide personalized treatment decisions in the...
The article spotlights duvakitug and the anti‑TL1A drug class as potential new options for ulcerative colitis and Crohn’s disease, especially for treatment‑experienced patients. Biomarker‑driven studies could help...
